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Continuity of care between physical and behavioral health
providers is a problem in today’s fragmented health care
system. Issues of privacy often do not allow sharing of
data among providers. For physical health providers and
insurers, the ability to identify patients with behavioral
health problems is important for care coordination and
targeting of disease management resources. OBJECTIVE:
Compare methods for identification of members with
psychoses using medical and pharmacy claims data in a
Medicaid HMO with a state-mandated behavioral health
carve-out. METHODS: Medical and pharmacy claims
data were reviewed for members 18 years or older identi-
fied by ICD-9CM codes 295–299.x or prescribed 90 days
of antipsychotic medications during calendar year 1998.
RESULTS: Of the 86,004 members with one year’s con-
tinuous enrollment, 776 had one or more medical claims
with a psychosis diagnosis and 2800 had used antipsy-
chotics. The 3166 unique members were categorized into
three groups: 410 members identified by both medical
and pharmacy claims, 366 identified by medical claims
only, and 2390 identified by pharmacy claims only. Iden-
tifying psychotic members on either medical or pharmacy
claims alone neglected 75% and 12% of the population
respectively. CONCLUSIONS: These results suggest a
majority of psychotic patients have not been recognized
by the physical health provider to have psychoses, are not
receiving physical as well as behavioral health services, or
physical providers are not coding these diagnoses. This
suggests continuity of care between the physical and be-
havioral health care carve-out providers is lacking. Fur-
ther data analysis will be performed to assess resource
use and patterns of care among these groups.
PDH17
ARE THE BRITISH GOVERNMENT’S 
HEALTHCARE REFORMS TARGETING 
PATIENT’S NEEDS?: EVIDENCE FROM A 
COMPARISON OF TWO GP SURVEYS ON 
MUSCULOSKELETAL CARE
Dickson DJ1, Hosie G1, English J2, Dickson AJ1
1PCR Society, Northallerton, N. Yorks, UK; 2Wokingham, 
Berks, UK
Clinical governance and Health Improvement Plans
(HIPs) targeted to patients’ primary healthcare needs are
central to the British government’s NHS reforms. The re-
forms obliged Primary Care Groups (PCGs) to heed pub-
lic concern over poor professional standards in the provi-
sion of NHS services. Real data on the impact of the
reforms is limited. The data presented here is novel. It
provides an annual assessment of the reforms’ effects on
primary care from the perspective of the patients’ doc-
tors, the General Practitioner (GP). OBJECTIVES: To
determine how PCGs are responding to the needs of GPs’
patients, and whether these needs are being attended to
better now than previously. METHODS: In November
1998, the Primary Care Rheumatology (PCR) society
mailed each of its members a questionnaire to assess the
impact of the Primary Care Act on musculoskeletal care.
A follow-up questionnaire was mailed in November
1999. Using Microsoft Excel, the numerical data was
quantified as means, medians or ranges, whilst free text
answers were summarised using categories based on the
responses. RESULTS: In November 1998 few HIPs were
concentrating on a prime area of concern to patients,
musculoskeletal care. In 1999, a gulf still exists between
health authorities’ perceptions of patients’ needs and
what GPs’ first-hand experience tells them. GPs’ financial
pressures are also growing and increasingly affecting
PCG drug budgets. CONCLUSIONS: GPs are struggling
to cope with the speed and scope of the reforms, with pa-
tients’ needs going unmet. With the current explosion in
new musculoskeletal medicines, the growing financial
pressures will be of concern to patients, politicians and
the pharmaceutical industry.
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OBJECTIVES: The South-East Asian region (China, South
Korea, Taiwan, the Philippines, Indonesia, Thailand,
